Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 113.29% is 128% above its 5-year average of 49.74%, near the high end of its 5-year range (18.04%–113.29%).
As of the fiscal period ended Wednesday, December 31, 2025. 53.87% above its 12-month average of 73.63%.
Annual fiscal-year return on equity; no daily interpolation.
RETURN ON EQUITY (ROE)
113.29%
RETURN ON EQUITY (ROE) AVG TTM
73.63%
RETURN ON EQUITY (ROE) AVG 3Y
65.34%
RETURN ON EQUITY (ROE) AVG 5Y
49.74%
RETURN ON EQUITY (ROE) AVG 10Y
30.23%
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+53.87%
CURRENT VS 3Y AVG
+73.39%
CURRENT VS 5Y AVG
+127.74%
CURRENT VS 10Y AVG
+274.70%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
10.89%
median of 79 covered companies
CURRENT VS SECTOR MEDIAN
+940.31%
vs the sector median at left
Medpace Holdings, Inc.
Market Cap
$16.11B
Return on Equity (ROE)
113.29%
TTM Avg
73.63%
3Y Avg
65.34%
5Y Avg
49.74%
Market Cap
$15.41B
Return on Equity (ROE)
-114.70%
TTM Avg
329.18%
3Y Avg
200.63%
5Y Avg
164.66%
Market Cap
$16.97B
Return on Equity (ROE)
10.37%
TTM Avg
13.30%
3Y Avg
15.60%
5Y Avg
24.66%
Market Cap
$14.80B
Return on Equity (ROE)
28.82%
TTM Avg
23.51%
3Y Avg
17.50%
5Y Avg
13.68%
Market Cap
$14.10B
Return on Equity (ROE)
2.86%
TTM Avg
4.70%
3Y Avg
4.67%
5Y Avg
11.22%
Market Cap
$18.17B
Return on Equity (ROE)
6.01%
TTM Avg
6.40%
3Y Avg
5.73%
5Y Avg
4.16%
Market Cap
$13.51B
Return on Equity (ROE)
-17.13%
TTM Avg
-12.46%
3Y Avg
-8.76%
5Y Avg
-1.37%
Market Cap
$12.55B
Return on Equity (ROE)
3.35%
TTM Avg
3.59%
3Y Avg
3.35%
5Y Avg
7.68%
Market Cap
$12.11B
Return on Equity (ROE)
9.77%
TTM Avg
10.54%
3Y Avg
10.84%
5Y Avg
19.93%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | $16.11B | 113.29% | 73.63% | 65.34% | 49.74% |
| DaVita Inc. (DVA)vs › | $15.41B | -114.70% | 329.18% | 200.63% | 164.66% |
| Hologic, Inc. (HOLX)vs › | $16.97B | 10.37% | 13.30% | 15.60% | 24.66% |
| Solventum Corporation (SOLV)vs › | $14.80B | 28.82% | 23.51% | 17.50% | 13.68% |
| The Cooper Companies, Inc. (COO)vs › | $14.10B | 2.86% | 4.70% | 4.67% | 11.22% |
| Zimmer Biomet Holdings, Inc. (ZBH)vs › | $18.17B | 6.01% | 6.40% | 5.73% | 4.16% |
| Baxter International Inc. (BAX)vs › | $13.51B | -17.13% | -12.46% | -8.76% | -1.37% |
| Revvity, Inc. (RVTY)vs › | $12.55B | 3.35% | 3.59% | 3.35% | 7.68% |
| Align Technology, Inc. (ALGN)vs › | $12.11B | 9.77% | 10.54% | 10.84% | 19.93% |
| Viatris Inc. (VTRS)vs › | $20.45B | -2.02% | -13.64% | -4.29% | -4.38% |
ROE
113.3%
ROA
23.9%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-31 | 98.27% |
| 2024-12-31 | 48.98% |
| 2023-12-31 | 50.60% |
| 2022-12-31 | 63.50% |
| 2021-12-31 | 19.08% |
| 2020-12-31 | 18.04% |
| 2019-12-31 | 13.83% |
| 2018-12-31 | 12.41% |
| 2017-12-31 | 7.77% |
| 2016-12-31 | 2.20% |
| 2015-12-31 | -2.10% |
| 2014-12-31 | -3.87% |
| 2013-12-31 | 0.00% |
